Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(29%)
Results Posted
150%(3 trials)
Terminated
2(29%)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_2
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting114%
completed229%
terminated229%
recruiting229%

Recent Activity

2 active trials
Showing 5 of 7
recruiting

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

NCT05860400
recruiting

Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study

NCT06845410
not_yet_recruitingnot_applicable

Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

NCT06981845
terminatedphase_2

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

NCT01044745
completedphase_2

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

NCT03483675
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05860400

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

Recruiting
NCT06845410

Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study

Recruiting
NCT06981845Not Applicable

Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

Not Yet Recruiting
NCT01044745Phase 2

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Terminated
NCT03483675Phase 2

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

Completed
NCT01672957

An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil

Completed
NCT00813501

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7